1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Oklahoma >
  6. Novartis Acquires Selexys Pharmaceuticals

M&A Deal Summary

Novartis Acquires Selexys Pharmaceuticals

On November 21, 2016, Novartis acquired life science company Selexys Pharmaceuticals

Acquisition Highlights
  • This is Novartis’ 10th transaction in the Life Science sector.
  • This is Novartis’ 12th transaction in the United States.
  • This is Novartis’ 1st transaction in Oklahoma.

M&A Deal Summary
Date 2016-11-21
Target Selexys Pharmaceuticals
Sector Life Science
Buyer(s) Novartis
Deal Type Add-on Acquisition

Target

Selexys Pharmaceuticals

Oklahoma City, Oklahoma, United States
Selexys Pharmaceuticals Corp. is a provider in the development of therapeutics in certain hematologic and inflammatory disorders.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Novartis

Basel, Switzerland
Category Company
Founded 1996
Sector Life Science
Employees104,323
Revenue 51.8B USD (2024)
DESCRIPTION
Novartis' corporate campus in Basel, Switzerland.
Novartis' corporate campus in Basel, Switzerland.

Novartis is a healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.

DEAL STATS #
Overall 13 of 36
Sector: Life Science M&A 10 of 30
Type: Add-on Acquisition M&A Deals 11 of 30
State: Oklahoma M&A 1 of 1
Country: United States M&A 12 of 28
Year: 2016 M&A 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-10-21 Admune Therapeutics

Danvers, Massachusetts, United States

Admune Therapeutics LLC is a clinical stage biotechnology company.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-12-16 Ziarco Pharma

Sandwich, United Kingdom

Ziarco Pharma Ltd. is a clinical stage biotechnology company, developing products to treat chronic inflammatory diseases with a focus on inflammatory skin disorders, in particular atopic dermatitis and psoriasis.

Buy -
Mergr

Solution for

Product

Company

Legal